Regeneron ends four clinical trials of its rolled-back Covid-19 antibody
Regeneron has terminated four studies of its monoclonal antibody combination, known as REGEN-COV, in recent days, months after the FDA halted use of the drug for which the federal government had doled out billions of dollars, according to the federal clinical trials database.
A BLA review for REGEN-COV has also gone beyond the previously extended PDUFA date of July 13, a company spokesperson confirmed to Endpoints News in an email.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,200+ biopharma pros reading Endpoints daily — and it's free.